Covera-HS is indicated for the management of hypertension and angina.

Covera-HS should be administered once daily at bedtime. Clinical trials explored dose ranges between 180 mg and 540 mg given at bedtime and found effects to persist throughout the dosing interval.

Covera-HS tablets should be swallowed whole and not chewed, broken, or crushed.

For both hypertension and angina the dose of Covera- HS should be individualized by titration. Initiate therapy with 180 mg of Covera-HS.

If an adequate response is not obtained with 180 mg of Covera-HS, the dose may be titrated upward in the following manner:

a) 240 mg each evening

b) 360 mg each evening (2 x 180 mg)

c) 480 mg each evening (2 x 240 mg)

When Covera-HS is administered at bedtime, office evaluation of blood pressure during morning and early afternoon hours is essentially a measure of peak effect. The usual evaluation of trough effect, which sometimes might be needed to evaluate the appropriateness of any given dose of Covera-HS, would be just prior to bedtime.

Covera-HS 240-mg tablets are pale yellow, round, film coated with COVERA–HS 2021 printed on one side, supplied as:

Covera-HS 180-mg tablets are lavender, round, film coated, with COVERA–HS 2011 printed on one side, supplied as:

Store at controlled room temperature 20°–25°C (68°–77°F) [see USP]. Dispense in tight, light-resistant containers.

Revised: May 2004. Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017. FDA Rev date: 1/31/2003

Bookmark this page: